Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end

Sensei Biotherapeutics, Inc.

2025-Q2 EPS reported -$9.36

Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).
Net loss $4.9M for Q2 2025 vs $7.1M for Q2 2024; R&D expenses decreased to $2.5M from $4.6M.
Phase 1/2 dose expansion cohort enrollment complete (64 patients); full data including 6-month PFS expected by year-end 2025.
Data to be presented at ESMO Congress 2025 (Oct 17-21) in a mini oral session.
Regained Nasdaq compliance after 1-for-20 reverse split effective June 16, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.